Genetics and immunity shape control of Epstein–Barr virus, large study finds
Epstein–Barr virus (EBV) remains in the body for life, but the amount detected in blood cells varies substantially between people. A large study published in Nature found that control of persistent EBV infection may be shaped by immune and behavioural factors as well as human genetic variants. The findings illuminate viral biology, but they are not a new diagnostic test or a reason to start treatment.
What the researchers studied
The authors analysed blood-based whole-genome sequencing data from 486,315 UK Biobank participants and 336,123 All of Us participants. Alongside human DNA, some samples contained short sequencing reads from the EBV genome. The researchers validated this signal with other methods and concluded that its presence can serve as an indirect marker of increased viral load in blood cells.
EBV reads were detected in 16.2% of UK Biobank participants and 21.8% of All of Us participants. This does not mean everyone else had never acquired EBV: according to the CDC, antibody testing shows evidence of current or past infection in about nine in ten adults. The research method was highly specific but insensitive for prior infection itself; it mainly selected samples with more detectable viral DNA.
Factors associated with poorer EBV control
EBV DNA was detected more often in people with HIV, people taking glucocorticoids or other immunosuppressive medicines, and current smokers. Among participants without identified immunosuppression, the signal appeared in 22.1% of current smokers versus 14.7% of current non-smokers. This is an association, not proof that smoking directly caused EBV reactivation in an individual.
The study also identified 28 genomic regions associated with EBV DNA detection: one in the major histocompatibility complex, which helps the immune system present and recognise antigens, and 27 outside it. The combined contribution of common variants outside that region was modest, with estimated heritability of about 2%. Genetics is therefore only one part of a complex interaction among the virus, immunity and environment.
Why the findings matter
EBV, also called human herpesvirus 4, infects B lymphocytes and becomes latent. Most infected people do not develop severe consequences. However, EBV is associated with multiple sclerosis and several cancers; the US National Cancer Institute lists Burkitt lymphoma, some other lymphomas, nasopharyngeal cancer and gastric cancer among them. Having EBV does not mean a person will develop any of these diseases.
In the new study, genetic profiles linked to a greater likelihood of detecting EBV DNA partly overlapped with profiles for multiple sclerosis, rheumatoid arthritis and several other immune-related conditions. Such statistical overlap does not show that increased viral load causes each condition. Instead, it generates hypotheses about the cells and immune pathways that researchers should investigate next.
What the study does not change today
- It does not establish a screening genetic test for “EBV control.”
- It does not support testing everyone with fatigue or other non-specific symptoms for EBV DNA.
- It does not show that antiviral treatment or “immune boosting” improves outcomes in otherwise healthy people without a defined diagnosis.
Persistent fever, markedly enlarged lymph nodes, severe weakness, difficulty breathing or swallowing, pain in the upper-left abdomen, or symptoms in a person with significant immune suppression warrant medical assessment. Testing should be chosen for the symptoms and clinical context, not on the basis of a single research marker.
Sources
- Schmidt A. et al. Host control of persistent Epstein–Barr virus infection. Nature, 2026
- CDC: About Epstein-Barr Virus
- National Cancer Institute: EBV definition
АС